Publication date: May 06, 2025
The SARS-CoV-2 virus poses a significant risk to immunocompromised patients, who display weakened immunity and reduced seroconversion following infection and vaccination. In this study, we recruited 19 hospitalized patients with immune disorders (ImCo) and 4 immunocompetent controls (ICC) with COVID-19. We evaluated their serological, humoral, and cellular immune responses at 90 days post-symptom onset. ICC patients showed robust B and T cell responses against SARS-CoV-2, indicated by detectable antibody levels, memory antibody-secreting cells (mASCs) towards the spike protein and spike-specific CD4 and CD8 T cells. ImCo patients showed impaired immune responses, with lower levels of B cell responses. Further subdivision of the ImCo patients demonstrates that solid organ transplant (SOT) patients generated B cell responses similar to ICC patients, whereas the other ImCo patients, including patients with hematological malignancies and anti-CD20 therapy, did not. Absolute T cell numbers and spike-specific CD4 and CD8 T cell responses were low in the ImCo patients at
Open Access PDF
| Concepts | Keywords |
|---|---|
| Cd4 | B cell |
| Humoral | cellular immunity |
| Immunocompromised | COVID-19 |
| Malignancies | humoral immunity |
| Organ | immunocompromised patients |
| immunosuppression | |
| SARS-CoV-2 | |
| T cell |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | immunocompromised patients |
| disease | MESH | seroconversion |
| disease | MESH | infection |
| disease | MESH | immune disorders |
| disease | MESH | COVID-19 |
| disease | IDO | symptom |
| disease | IDO | cell |
| disease | IDO | protein |
| disease | MESH | hematological malignancies |
| disease | MESH | Infectious Diseases |
| drug | DRUGBANK | Indoleacetic acid |
| disease | IDO | immunosuppression |